Association of the ADRA1A gene and the severity of metabolic abnormalities in patients with schizophrenia

https://doi.org/10.1016/j.pnpbp.2011.10.011Get rights and content

Abstract

Patients with schizophrenia have a higher risk of developing metabolic abnormalities and their associated diseases. Some studies found that the accumulative number of metabolic syndrome components was associated with the severity of metabolic abnormalities. The purpose of this study was to examine the roles of the ADRA1A, ADRA2A, ADRB3, and 5HT2A genes in the risk of having more severe metabolic abnormalities among patients with schizophrenia. We studied a sample of 232 chronic inpatients with schizophrenia (120 males and 112 females) to explore the associations between the four candidate genes and the severity of metabolic syndrome by accumulative number of the components. Four single nucleotide polymorphisms in the candidate genes were genotyped, including the Arg347Cys in ADRA1A, the C1291G in ADRA2A, the Try64Arg in ADRB3, and the T102C in 5HT2A. An association between the accumulative number of metabolic syndrome components and the ADRA1A gene was found after adjusting age, sex, and other related variables (p-value = 0.036). Presence of the Arg347 allele in the ADRA1A gene is a risk factor for having more severe metabolic abnormalities. These findings suggest a medical attention of closely monitoring metabolic risks for schizophrenia patients with high-risk genotypes.

Highlights

► A relationship between the metabolic syndrome components and the ADRA1A gene. ► The roles of the ADRA1A, ADRA2A, ADRB3, and 5HT2A genes in metabolic syndrome. ► Emphasis of a high prevalence of metabolic syndrome among people with schizophrenia. ► Psychiatric pharmacogenetics for susceptibility to the metabolic syndrome.

Introduction

Metabolic syndrome is a clustering of several interrelated cardiovascular risk factors. The National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (NCEP Adult Treatment Panel III [NCEP ATP III]) (Grundy et al., 2005) defines 5 criteria for clinical identification of metabolic syndrome, including abdominal obesity, hypertriglyceridemia, low level of high-density lipoprotein cholesterol (HDL-C), hypertension, and elevated fasting glucose level, with diagnosis requiring 3 or more components. Several studies have shown that metabolic syndrome is associated with the risk of coronary heart disease, type 2 diabetes mellitus, hypertension, cardiovascular disease, and all-cause mortality (Alberti et al., 2005, Einhorn et al., 2003, Lakka et al., 2002). The prevalence of cardiovascular disease, death from cardiovascular causes (Ryan and Thakore, 2002), and the risk of developing metabolic abnormalities (Marder et al., 2004, Suvisaari et al., 2007, Thakore, 2005) are higher in patients with schizophrenia than in the general population. This phenomenon may be associated with intrinsic metabolic deficiencies in schizophrenia (Thakore, 2005), antipsychotic medication, and with many lifestyle-related cardiovascular risk factors such as lack of exercise, poor diet habits, and smoking, among others (Silverstein et al., 2009, Vancampfort et al., 2010). On the other hand, some studies found that the accumulative number of metabolic syndrome components was associated with mortality from cardiovascular disease and coronary heart disease, and the incidence of ischemic stroke (Ford, 2004, Rodriguez-Colon et al., 2009).

Clinical observation of substantial inter-individual and population differences in weight gain in patients with schizophrenia has implicated genetic involvement. Basile et al. (2001) first tested 10 genetic polymorphisms across 9 candidate genes, including the 5-HT2C, 2A, and 1A receptor genes (HTR2C/2A/1A), the histamine H1 and H2 receptor genes (H1R/H2R), the cytochrome P450 1A2 gene (CYP1A2), the adrenergic alpha1A and beta3 receptor genes (ADRA1A/ADRB3), and the tumor necrosis factor-alpha gene (TNF-α) in 80 patients with schizophrenia (58 Caucasians, 22 African-Americans). Associations between weight gain and the ADRB3, ADRA1A, TNF-α, and HTR2C genes were identified. Many related studies on genetics were conducted thereafter, and the results of these studies are summarized below. First, the ADRA1A gene was shown to be related to obesity and other cardiovascular risk factors (Freitas et al., 2008, Gunes et al., 2009, Ochoa et al., 2004, Phares et al., 2004, Piascik and Perez, 2001). One recent study found an association between the ADRA1A gene and weight gain in 401 Taiwanese chronic schizophrenia patients exposed to antipsychotics (Liu et al., 2010). Second, a role for ADRA2A C1291G polymorphism in olanzapine- and/or clozapine-induced weight gain was reported in Korean (Park et al., 2006), Taiwanese (Wang et al., 2005), and European-American and African-American (Sickert et al., 2009) patients with schizophrenia. Third, the ADRB3 Trp64Arg polymorphism gene has been reported to be associated with obesity, features of metabolic syndrome, insulin resistance syndrome, and the early onset of diabetes mellitus (Sakane et al., 1997, Walston et al., 1995). However, a study in a Taiwanese population showed a lack of association between Trp64Arg in the ADRB3 gene and clozapine-induced weight gain (Tsai et al., 2004), and little or no influence on body weight, body mass index (BMI), or atypical antipsychotics-induced weight gain was reported in other studies (Arii et al., 1997, Masuo et al., 2005, Matsushita et al., 2003). Fourth, a study that included 164 Japanese patients with schizophrenia examined the genetic association with multiple candidate genes and identified genetic variants of the 5HT2A, HTR2C, ADRB3, and G-protein β3 subunit (GNB3) genes as genetic risk factors for olanzapine-induced weight gain (Ujike et al., 2008).

In view of these findings, we aimed to examine the roles of the ADRA1A, ADRA2A, ADRB3, and 5HT2A genes in metabolic syndrome among patients with schizophrenia. Because metabolic syndrome is a clustering of several interrelated cardiovascular risk factors, application of the concept of the accumulative number of metabolic syndrome components provides an appropriate index for the genetic study of metabolic syndrome. In this study, we tried to investigate the associations between the four candidate gene polymorphisms and the accumulative number of metabolic syndrome components.

Section snippets

Participants

Patients who met the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) criteria for schizophrenia or schizoaffective disorder were recruited for this study. Participants were excluded if they had any axis I or II disorders other than the primary diagnosis of schizophrenia or schizoaffective disorder, any neurological condition, or head trauma. A total of 232 unrelated inpatients (120 males and 112 females) with a mean age of 43.4 ± 11.6 years were

Baseline characteristics

Two hundred and thirty-two patients were available for the analysis. Among these subjects, twenty-two subjects had incomplete data on metabolic syndrome components. The model fitness test indicated no significant effect of the missing components on the overall performance (data not shown), and thus these subjects were left in the following analysis. The demographic characteristics of the participants, grouped by the accumulative number of metabolic syndrome components (≧ 3, severe form; < 3, mild

Discussion

In this study, we found a significant association between the Arg347 allele of the ADRA1A gene and the severity of metabolic abnormalities in patients with schizophrenia in an ordinal logistic regression model. As many studies have revealed that patients with schizophrenia have a higher risk of developing metabolic abnormalities and increased risks of developing type 2 diabetes mellitus, cardiovascular disease, cerebrovascular disease, and cardiovascular mortality (Marder et al., 2004,

Conclusions

In conclusion, this study showed a relationship between the accumulative number of metabolic syndrome components and the ADRA1A gene. Presence of the Arg347 allele in the ADRA1A gene is a risk factor for the increase of the accumulative number of metabolic syndrome components, which means a higher risk of having more severe metabolic abnormalities. These findings imply a potential clinical application in psychiatric pharmacogenetics that chronic schizophrenia patients with a high risk genotype

Acknowledgments

We thank the lab technicians, who devoted much time and effort to this study. The project funding was provided by a grant from the Taoyuan Mental Hospital.

References (45)

  • K. Arii et al.

    Trp64Arg mutation of beta 3-adrenergic receptor and insulin sensitivity in subjects with glucose intolerance

    Internal Medicine

    (1997)
  • V.S. Basile et al.

    Genetic dissection of atypical antipsychotic-induced weight gain: novel preliminary data on the pharmacogenetic puzzle

    The Journal of Clinical Psychiatry

    (2001)
  • O. Bayturan et al.

    The metabolic syndrome, its component risk factors, and progression of coronary atherosclerosis

    Archives of Internal Medicine

    (2010)
  • D. Einhorn et al.

    American College of Endocrinology position statement on the insulin resistance syndrome

    Endocrine Practice

    (2003)
  • E.S. Ford

    The metabolic syndrome and mortality from cardiovascular disease and all-causes: findings from the National Health and Nutrition Examination Survey II Mortality Study

    Atherosclerosis

    (2004)
  • E.S. Ford et al.

    Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey

    JAMA : The Journal of the American Medical Association

    (2002)
  • S.R. Freitas et al.

    Association of alpha1a-adrenergic receptor polymorphism and blood pressure phenotypes in the Brazilian population

    BMC Cardiovascular Disorders

    (2008)
  • H.C. Gerstein et al.

    The relationship between dysglycemia and atherosclerosis in South Asian, Chinese, and European individuals in Canada: a randomly sampled cross-sectional study

    Diabetes Care

    (2003)
  • S.M. Grundy et al.

    Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition

    Circulation

    (2004)
  • S.M. Grundy et al.

    Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement

    Circulation

    (2005)
  • D. Gu et al.

    Association of alpha1A adrenergic receptor gene variants on chromosome 8p21 with human stage 2 hypertension

    Journal of Hypertension

    (2006)
  • A. Gunes et al.

    Association between HTR2C and HTR2A polymorphisms and metabolic abnormalities in patients treated with olanzapine or clozapine

    Journal of Clinical Psychopharmacology

    (2009)
  • Cited by (21)

    • A systematic review of genetic variants associated with metabolic syndrome in patients with schizophrenia

      2016, Schizophrenia Research
      Citation Excerpt :

      HTR2A is therefore an interesting pleiotropic candidate gene to investigate in the comorbidity of MetS and schizophrenia. Two studies investigated variants in HTR2A (Gunes et al., 2009; Cheng et al., 2012). However only one study reported an association whereby individuals with haplotype 2 (rs6311 A-allele, rs6313 T-allele, rs6314 C-allele) had significantly higher C peptide, a peptide released from the pancreatic beta-cells during cleavage of insulin from proinsulin, levels compared to those with haplotype 3 (rs6311 A-allele, rs6313 T-allele, rs6314 T-allele), both in the OLZ treated group and in the overall study population (Gunes et al., 2009).

    • Pharmacogenomics in Psychiatry Practice: The Value and the Challenges

      2022, International Journal of Molecular Sciences
    • Transcriptional identification of potential biomarkers of lung adenocarcinoma

      2020, Journal of Shanghai Jiaotong University (Medical Science)
    View all citing articles on Scopus
    1

    These two authors contributed equally to this work.

    View full text